To compare Amgn and Eli Lilly to performances affected by deductibles and bad weather to affects to SCRC, is like comparing apples to oranges.
Amgn has a $119 Billion Market Cap, $20.4 Billion in Sales
Eli Lilly has a $79 Billion Market Cap, $ 23 Billion in Sales
SCRC has a $24 Million Market Cap, A projected sales of $60 Million
Amgn and Eli Lilly are vast leaders in their industry and diversified and are research and manufacturing and in global markets as compared to SCRC.
The effect of patients deductibles in the beginning of the year are more greatly to effect SCRC numbers percentage wise than to Amgn and Eli Lilly.
So once again we have to clear the air for the distortion of comparison of facts being printed here. As I said once again, this is getting old.
To try to insinuate that there is something greater to explain for the loss of Sales other than deductible's resetting, holidays and storm related days in N.J. the predominate area for MAV is suspect at best.